27 results
8-K
EX-10.1
SLRN
Acelyrin, Inc.
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
” transactions pursuant to the Company’s policy regarding satisfaction of certain tax obligations of Employee incurred with vesting and settlement
DEF 14A
SLRN
Acelyrin, Inc.
22 Apr 24
Definitive proxy
4:10pm
)Assumes all time-based vesting criteria is satisfied in full, and assumes 100% satisfaction of PSU Strategic Milestones.
Outstanding Equity Awards
10-K
2023 FY
SLRN
Acelyrin, Inc.
28 Mar 24
Annual report
4:21pm
the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may … or implementation of our clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our
10-Q
qa8lrwc1gwfy9x3n0
15 Jun 23
Quarterly report
4:19pm
S-8
EX-5.1
n8drn8jcb2ppux4
8 May 23
Registration of securities for employees
5:27pm
424B4
5lsas ltw
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1MEF
EX-5.1
csn6785ku1sr3ml20bug
4 May 23
Registration of additional securities for an S-1
5:55pm
S-1/A
EX-10.5
0u2w6
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.10
1du8 hysgdtvzs
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.3
megnawjmlei3aqcf
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.9
rp06x9
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.14
p1g6sazzl
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-5.1
vn34jsdgov nz
1 May 23
IPO registration (amended)
6:10am
S-1/A
5wfapqc7qpe58q2sd
1 May 23
IPO registration (amended)
6:10am